Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3709 | Standard Of Care (SOC) Wiki | 1.00 |
| drug3384 | Rivaroxaban Wiki | 0.45 |
| drug2916 | Placebo Wiki | 0.04 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Primary Objective: To evaluate the effect of SAR443122 relative to the control arm on the hyperinflammatory state as measured by C-reactive protein (CRP) levels in adult patients hospitalized with severe COVID-19 Secondary Objectives: - To evaluate the time to onset of effect of SAR443122 relative to the control arm on the hyperinflammatory state as measured by CRP levels - To evaluate the time to onset of effect of SAR443122 relative to the control arm on oxygenation status - To evaluate the effect of SAR443122 relative to the control arm on oxygenation status - To evaluate the effect of SAR443122 relative to the control arm on total duration of supplemental oxygen requirement - To evaluate the effect of SAR443122 relative to the control arm on length of ventilator support needed - To evaluate the effect of SAR443122 relative to the control arm on laboratory markers of severe COVID-19 - To evaluate the effect of SAR443122 relative to the control arm on mortality - To evaluate the effect of SAR443122 relative to the control arm on need for thrombolytic therapy - To evaluate the effect of SAR443122 relative to the control arm on need for vasopressor treatment - To evaluate the safety of SAR443122 as compared to the control arm up to End of Study
Description: Relative change from baseline in CRP level on Day 7
Measure: Relative change from baseline in CRP level Time: Day 7Description: The time to 50% decrease from baseline in CRP level
Measure: Time to 50% decrease from baseline in CRP level Time: Baseline to Day 28Description: The time to improvement of oxygenation as measured by oxygen saturation >/=92% breathing room air over 48 hrs or until discharge
Measure: Time to improvement of oxygenation Time: Baseline to Day 28Description: Change from baseline in SPO2/FiO2 ratio at Day 7
Measure: Change from baseline in SPO2/FiO2 ratio Time: Day 7Description: Number of Days without need for oxygen support and alive (oxygen saturation >=92% breathing room air) up to Day 28
Measure: Number of Days without need for oxygen support and alive Time: Baseline to Day 28Description: Numbers of Ventilator-free days and alive up to Day 28
Measure: Numbers of Ventilator-free days and alive Time: Baseline to Day 28Description: Change from baseline in white blood cell count and differential blood lymphocytes at Day 7 and End of treatment (EOT)
Measure: Change from baseline in markers of inflammation: white blood cell count and differential blood lymphocytes Time: Day 7 and Day 15Description: Change from baseline in neutrophil to lymphocyte ratio at Day 7 and EOT
Measure: Change from baseline in marker of inflammation: neutrophil to lymphocyte ratio Time: Day 7 and Day 15Description: Change from baseline in IL-6 at Day 7 and EOT
Measure: Change from baseline in marker of inflammation: interleukin 6 (IL-6) Time: Day 7 and Day 15Description: Change from baseline in D-Dimer at Day 7 and EOT
Measure: Change from baseline in D-Dimer Time: Day 7 and Day 15Description: Incidence of Deaths up to Day 28
Measure: Incidence of Deaths Time: Baseline to Day 28Description: Percentage of participants receiving thrombolytic treatment up to Day 28
Measure: Percentage of participants receiving thrombolytic treatment Time: Baseline to Day 28Description: Percentage of participants receiving vasopressor treatment up to Day 28
Measure: Percentage of participants receiving vasopressor treatment Time: Baseline to Day 28Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports